Clinical Trial Update: Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors [Phase 3]

View source ↗

Summary

This is a Phase 3 trial testing sirolimus (albumin-bound) in combination with fulvestrant for HR+/HER2- advanced/metastatic breast cancer patients previously tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Sirolimus (albumin-bound) for injection (sirolimus)

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: HR+/HER2- Advanced/Metastatic Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING